Q.1
From a patient perspective, what principal reasons have driven the desire for a greater durability of response for patients?
*
Minimising the financial burden caused by managing psoriasis
Providing a sense of normality and reducing the impact on quality of life
Make it easier to remember to take medications
Continue
Q.2
Which IL-23 inhibitor recently had 5-year efficacy and safety data presented at EADV 2020?
*
Guselkumab
Tildrakizumab
Risankizumab
Continue
Q.3
How do IL-23 inhibitors compare to older biologic agents in terms of their long-term safety and efficacy?
*
Reduced risk of opportunistic infection
Increased safety, durability, and maintenance of the treatment response
Fewer serious adverse events from staying on the same compound
All of the above
Continue
Q.4
Which of these is NOT a notable impact of the COVID-19 pandemic in clinical practice?
*
IL-17 and 23 inhibitors increase the risk of COVID-19 infection
There is a greater need for information, education, and continuous treatment
Patients with comorbidities have a higher risk of adverse outcomes
Continue
Q.5
Is there any strong evidence to suggest that patients with psoriasis are at increased risk of catching or developing a severe case of COVID-19?
*
Yes
No
Continue
1 / 5